AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Novo Nordisk, manufacturer of the weight loss jab Wegovy, has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations (Alamy/PA ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Novo Nordisk A/S's recent 44% decline combined with impressive Q4 2024 and fiscal 2024 results with strong sales and profit growth raise the question if the company is a “Buy” again.

Novo Nordisk's U.S.-listed shares rose 5% in intraday ... to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with ...

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive said, as tensions simmer between Copenhagen and Washington. Trump has ...